Boundless Bio, Inc.
BOLD Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$2.41
KIRA · Stoqly’s AI analyst, in plain words
- Boundless Bio, Inc. lost $58.2M in fiscal 2025.
- Free cash flow was −$47.2M in fiscal 2025, — of revenue.
Market cap
$54.1M
P/E
—
Revenue
—
Net income
−$58.2M
Free cash flow
−$47.2M
Operating margin
—
Boundless Bio, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$58.2M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Boundless Bio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 9, 2026
- Legal name
- Boundless Bio, Inc.
- CIK
- 0001782303
Boundless Bio, Inc. · BOLD
Results and finances
The last 3 fiscal years. Amounts in USD.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Sales and profit | |||
| Net income | −$49.4M | −$65.4M | −$58.2M |
| Diluted EPS | −$40.65 | −$3.85 | −$2.60 |
| Cash | |||
| Cash from operations | −$46.9M | −$60.8M | −$46.7M |
| Capital expenditure | $0.6M | $2.5M | $0.5M |
| Free cash flow | −$47.5M | −$63.4M | −$47.2M |
| Share count change | — | 1,296.7% | 31.7% |
| Debt and strength | |||
| Cash and short-term investments | $121M | $152M | $108M |
| Shareholders' equity | −$127M | $151M | $98.7M |
| Current ratio | 13.3x | 19.0x | 8.7x |
| Returns and quality | |||
| Return on equity | — | −554.9% | −46.7% |
| Return on tangible equity | — | −43.4% | −59.0% |
| Altman Z'' | −14.7 | 1.9 | −2.3 |
Insiders bought, 12 months
$1.9M
1 insider
Insiders sold, 12 months
$0.1M
2 insiders
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Boundless Bio, Inc. · BOLD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.41 a share, the company is worth $54.1M.
Source: SEC EDGAR XBRL filings (CIK 0001782303). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.